Citi lowered its target price for Lee's Pharm (00950) to HK$6.5 from HK$6.83 and maintained its "buy" rating.
The research house said downside risks that could cause the stock to fail to meet the target price include further tender price cut; slower-than-expected new product launches; sales under agency model might face two-invoice policy impact in some provinces.
全新節目《說說心理話》青少年不可以戀愛！？真實個案講述驚心動魄經歷► 即睇
